<DOC>
	<DOCNO>NCT00492063</DOCNO>
	<brief_summary>The present study aim evaluate safety immunogenicity new influenza subunit vaccine produce Madin Darby Canine Kidney ( MDCK ) cell healthy adult elderly subject .</brief_summary>
	<brief_title>Safety Immunogenicity Cell Culture-derived Influenza Vaccine Healthy Adults Elderly</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . 18 60 year age ( first age group ) OR 60 year age ( second age group ) 2. mentally competent understand nature , scope consequence study 3. able willing give write informed consent prior study entry 4. available visit schedule study 5. residence study area 6. good health determine : 1. medical history , 2. physical examination , 3. clinical judgment investigator . 1. unable unwilling give write informed consent participate study 2. suffer acute infectious disease 3. serious disease : 1. cancer ( except benign localize skin cancer non metastatic prostate cancer currently treat chemotherapy ) , _ 2. autoimmune disease ( include rheumatoid arthritis ) , 3. advance arteriosclerotic disease complicate diabetes mellitus , 4. chronic obstructive pulmonary disease ( COPD ) require oxygen therapy , 5. acute progressive hepatic disease , 6. acute progressive renal disease , 7. congestive heart failure 4. surgery plan study period 5. bleeding diathesis 6. history hypersensitivity component study medication chemically related substance , allergy egg egg product 7. know suspected impairment/alteration immune function result : 1. receipt immunosuppressive therapy ( cortical steroid cancer chemotherapy ) , 2. receipt immunostimulants , 3. receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within past 3 month full length study , 4. high risk develop immunocompromising disease within past 6 month 8. history drug alcohol abuse 9. laboratory confirm influenza disease past 6 month 10. receive influenza vaccine within past 6 month 11. receive another vaccine investigational agent within past 60 day , plan vaccination within 3 week follow study vaccination 12. acute respiratory disease infection require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) experience fever ≥ 38°C within past 3 day 13. pregnant woman woman refuse use reliable contraceptive method throughout study ( 180 day ) 14. condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>MDCK</keyword>
	<keyword>cell culture-derived</keyword>
	<keyword>subunit influenza vaccine</keyword>
	<keyword>influenza prevention</keyword>
</DOC>